SLS ▲ +1.4% - SELLAS Life Sciences Group, Inc. $SLS - SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer SELLAS Life Sciences rose 1.4% following an announcement that the company will present preclinical data on its SLS009 candidate targeting pancreatic ductal adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer. The presentation offers investors visibility into the company's pipeline progress in an oncology indication, which typically supports clinical-stage biotech valuations. 02-SEP-2026 08:31 AM ET